Site 42 - Dana-Farber Cancer Institute, EDDC — Boston, Massachusetts

Site 42 - Dana-Farber Cancer Institute, EDDC is a clinical research site located in Boston, Massachusetts, United States 02215.

Crixeo Health Trust Score: 56/100 (POOR). This profile has not yet been claimed by the site owner.

Site 42 - Dana-Farber Cancer Institute, EDDC has participated in 1 clinical trials.

Therapeutic areas: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer.

Sponsors: Carrick Therapeutics Limited.

Sponsor Feasibility Report

Trust Score: 56/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site 42 - Dana-Farber Cancer Institute, EDDC?

Site 42 - Dana-Farber Cancer Institute, EDDC has a Crixeo Trust Score of 56/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site 42 - Dana-Farber Cancer Institute, EDDC conducted?

Site 42 - Dana-Farber Cancer Institute, EDDC has 1 clinical trials on record. Their work covers Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer.

Is Site 42 - Dana-Farber Cancer Institute, EDDC accredited by Crixeo Health?

Site 42 - Dana-Farber Cancer Institute, EDDC has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site 42 - Dana-Farber Cancer Institute, EDDC?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.